Financhill
Buy
69

MLAB Quote, Financials, Valuation and Earnings

Last price:
$131.08
Seasonality move :
10.17%
Day range:
$129.21 - $132.99
52-week range:
$83.68 - $147.34
Dividend yield:
0.49%
P/E ratio:
--
P/S ratio:
3.11x
P/B ratio:
4.41x
Volume:
31K
Avg. volume:
38K
1-year change:
36.57%
Market cap:
$711.8M
Revenue:
$216.2M
EPS (TTM):
-$45.56

Analysts' Opinion

  • Consensus Rating
    Mesa Laboratories has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $133.33, Mesa Laboratories has an estimated upside of 1.74% from its current price of $131.05.
  • Price Target Downside
    According to analysts, the lowest downside price target is $120.00 representing 100% downside risk from its current price of $131.05.

Fair Value

  • According to the consensus of 4 analysts, Mesa Laboratories has 1.74% upside to fair value with a price target of $133.33 per share.

MLAB vs. S&P 500

  • Over the past 5 trading days, Mesa Laboratories has underperformed the S&P 500 by -7.94% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Mesa Laboratories does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Mesa Laboratories has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Mesa Laboratories reported revenues of $57.8M.

Earnings Growth

  • Mesa Laboratories has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Mesa Laboratories reported earnings per share of $0.63.
Enterprise value:
892.4M
EV / Invested capital:
--
Price / LTM sales:
3.11x
EV / EBIT:
--
EV / Revenue:
3.91x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
24.94x
Price / Operating cash flow:
19.85x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$142.7M
Return On Assets:
-45.15%
Net Income Margin (TTM):
-107.56%
Return On Equity:
-98.4%
Return On Invested Capital:
-53.61%
Operating Margin:
6.07%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $222.8M $213.7M $228.4M $53.2M $57.8M
Gross Profit $131.5M $129.3M $142.7M $32.1M $35.5M
Operating Income -$3.2M $3.2M $12.3M -$60K $3.5M
EBITDA $32.5M $37M -$229.2M $7.7M $12.9M
Diluted EPS -$0.76 -$0.14 -$45.56 -$0.23 $0.63
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $280.1M $319.4M $116.3M $117.7M $108M
Total Assets $588.9M $609.1M $656.2M $637.2M $454.1M
Current Liabilities $19.5M $28.7M $41.5M $39.8M $153.2M
Total Liabilities $196.5M $209.7M $282M $249.4M $292.6M
Total Equity $392.4M $399.4M $374.2M $387.8M $161.5M
Total Debt $142.9M $168.9M $196.8M $170.7M $205M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $32.9M $40M $40.1M $9.8M $5.3M
Cash From Investing -$305.5M -$8.5M -$83.1M -$634K -$1.8M
Cash From Financing $31.1M -$28.4M $30.2M -$5.6M -$8.6M
Free Cash Flow $28.2M $36.4M $35.8M $9.1M $3.5M
MLAB
Sector
Market Cap
$711.8M
$46.7M
Price % of 52-Week High
88.95%
46.54%
Dividend Yield
0.49%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
36.57%
-33.88%
Beta (5-Year)
0.820
0.752
Dividend yield:
0.49%
Annualized payout:
$0.64
Payout ratio:
-1.41%
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $136.50
200-day SMA
Buy
Level $115.80
Bollinger Bands (100)
Buy
Level 115.47 - 134.67
Chaikin Money Flow
Buy
Level 3.6M
20-day SMA
Sell
Level $133.96
Relative Strength Index (RSI14)
Sell
Level 49.73
ADX Line
Sell
Level 21.82
Williams %R
Neutral
Level -75.2726
50-day SMA
Buy
Level $123.57
MACD (12, 26)
Buy
Level 2.98
25-day Aroon Oscillator
Buy
Level 76
On Balance Volume
Neutral
Level 7.7M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-0.7319)
Sell
CA Score (Annual)
Level (-2.5718)
Buy
Beneish M-Score (Annual)
Level (-5.9713)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (3.9193)
Buy
Piotroski F Score (Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Stock Forecast FAQ

In the current month, MLAB has received 2 Buy ratings 1 Hold ratings, and 1 Sell ratings. The MLAB average analyst price target in the past 3 months is $133.33.

  • Where Will Mesa Laboratories Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Mesa Laboratories share price will rise to $133.33 per share over the next 12 months.

  • What Do Analysts Say About Mesa Laboratories?

    Analysts are divided on their view about Mesa Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mesa Laboratories is a Sell and believe this share price will drop from its current level to $120.00.

  • What Is Mesa Laboratories's Price Target?

    The price target for Mesa Laboratories over the next 1-year time period is forecast to be $133.33 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is MLAB A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Mesa Laboratories is a Buy. 2 of 4 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of MLAB?

    You can purchase shares of Mesa Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mesa Laboratories shares.

  • What Is The Mesa Laboratories Share Price Today?

    Mesa Laboratories was last trading at $131.08 per share. This represents the most recent stock quote for Mesa Laboratories. Yesterday, Mesa Laboratories closed at $131.05 per share.

  • How To Buy Mesa Laboratories Stock Online?

    In order to purchase Mesa Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Target a Dividend King?
Is Target a Dividend King?

Popular retail giant Target Corporation (NYSE:TGT) has been in a…

Is COWZ ETF a Good Investment?
Is COWZ ETF a Good Investment?

There’s a reason even Warren Buffett advocates his heirs to…

3 Stocks Buffett Is Betting On
3 Stocks Buffett Is Betting On

Warren Buffett appeared to take a hard look at the…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Sell
44
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 110x

Sell
40
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
72
HEES alert for Jan 15

H&E Equipment Services [HEES] is up 105.42% over the past day.

Sell
26
SIG alert for Jan 15

Signet Jewelers [SIG] is down 21.66% over the past day.

Sell
45
WGS alert for Jan 15

GeneDx Holdings [WGS] is down 15.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock